Printer Friendly

J&J verdict likely to increase attention on lawsuits, says Credit Suisse.

After a Missouri jury on Thursday ordered Johnson & Johnson to pay $4.69B to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer, Credit Suisse analyst Vamil Divan said the large number of ongoing litigations are gaining the attention of investors and is not expected to slow. Given the number of cases related to both talc and mesh and the size of the potential verdicts, Divan says it is "challenging" to put reasonable ranges on what J&J's ultimate liability may end up being, though he notes that J&J has been able to overturn many of the cases and has appealed all of the unfavorable verdicts. Divan maintains an Outperform rating and $151 price target.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jul 13, 2018
Previous Article:Inter Parfums price target raised to $62 from $57 at DA Davidson.
Next Article:CDC says continues to recommend people not eat Kellogg's Honey Smacks cereal.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters